* Contravir initiates head-to-head phase 2a clinical study
of cmx157 versus. viread for treating hepatitis b
The post BRIEF-Contravir Pharma initiates mid-stage study of CMX157 for treating hepatitis B appeared first on NASDAQ.
BRIEF-Contravir Pharma initiates mid-stage study of CMX157 for treating hepatitis B
